 Jeffrey B. Matthews
Concepts (521)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| General Surgery | 12 | 2021 | 218 | 3.650 |
Why?
| | Pancreas | 7 | 2017 | 254 | 2.730 |
Why?
| | Pancreatitis, Chronic | 12 | 2021 | 50 | 2.650 |
Why?
| | Sodium-Potassium-Chloride Symporters | 7 | 2012 | 24 | 2.380 |
Why?
| | Islets of Langerhans Transplantation | 13 | 2021 | 208 | 2.050 |
Why?
| | Specialties, Surgical | 6 | 2021 | 55 | 2.040 |
Why?
| | Chlorides | 6 | 2012 | 116 | 1.980 |
Why?
| | Coronavirus Infections | 7 | 2020 | 283 | 1.900 |
Why?
| | Pneumonia, Viral | 7 | 2020 | 309 | 1.890 |
Why?
| | Pandemics | 10 | 2020 | 465 | 1.840 |
Why?
| | Surgical Procedures, Operative | 5 | 2020 | 186 | 1.830 |
Why?
| | Digestive System Surgical Procedures | 6 | 2019 | 135 | 1.780 |
Why?
| | Pancreatectomy | 15 | 2021 | 173 | 1.740 |
Why?
| | Epithelial Cells | 10 | 2012 | 605 | 1.610 |
Why?
| | Colon | 6 | 2012 | 485 | 1.550 |
Why?
| | Endosonography | 6 | 2020 | 130 | 1.420 |
Why?
| | Protein Kinase C | 7 | 2005 | 300 | 1.380 |
Why?
| | Intestinal Mucosa | 11 | 2012 | 887 | 1.350 |
Why?
| | Surgery Department, Hospital | 3 | 2020 | 43 | 1.250 |
Why?
| | Education, Medical, Graduate | 6 | 2020 | 325 | 1.230 |
Why?
| | Quaternary Ammonium Compounds | 4 | 2007 | 89 | 1.220 |
Why?
| | Pancreatitis, Acute Necrotizing | 4 | 2012 | 18 | 1.180 |
Why?
| | Gastroenterostomy | 2 | 2020 | 6 | 1.090 |
Why?
| | Humans | 97 | 2021 | 80482 | 1.040 |
Why?
| | Pancreatic Neoplasms | 7 | 2014 | 692 | 1.040 |
Why?
| | Infection Control | 4 | 2020 | 136 | 1.030 |
Why?
| | Pancreaticoduodenectomy | 7 | 2016 | 101 | 0.950 |
Why?
| | Disaster Planning | 1 | 2021 | 31 | 0.930 |
Why?
| | Patient Selection | 4 | 2020 | 687 | 0.920 |
Why?
| | Truth Disclosure | 2 | 2021 | 86 | 0.910 |
Why?
| | Checklist | 1 | 2021 | 51 | 0.910 |
Why?
| | Judgment | 1 | 2021 | 56 | 0.900 |
Why?
| | Advisory Committees | 2 | 2020 | 83 | 0.890 |
Why?
| | Education, Medical, Continuing | 1 | 2021 | 101 | 0.860 |
Why?
| | Accreditation | 1 | 2020 | 51 | 0.860 |
Why?
| | Peptic Ulcer | 1 | 2019 | 19 | 0.840 |
Why?
| | Immune Tolerance | 4 | 2010 | 334 | 0.830 |
Why?
| | Surgical Wound Infection | 3 | 2019 | 183 | 0.810 |
Why?
| | Music | 1 | 2019 | 29 | 0.810 |
Why?
| | Disease Transmission, Infectious | 1 | 2020 | 65 | 0.800 |
Why?
| | Quality of Health Care | 2 | 2020 | 353 | 0.800 |
Why?
| | Health Resources | 1 | 2020 | 77 | 0.800 |
Why?
| | Protein Kinase C-epsilon | 6 | 2010 | 22 | 0.800 |
Why?
| | Cyclic AMP | 3 | 2010 | 280 | 0.780 |
Why?
| | Gastric Outlet Obstruction | 2 | 2017 | 10 | 0.760 |
Why?
| | Tetradecanoylphorbol Acetate | 5 | 2010 | 154 | 0.730 |
Why?
| | Informed Consent | 1 | 2020 | 241 | 0.730 |
Why?
| | Spinal Cord Injuries | 1 | 2017 | 49 | 0.710 |
Why?
| | Decision Making | 2 | 2020 | 615 | 0.710 |
Why?
| | Electronic Health Records | 1 | 2020 | 260 | 0.700 |
Why?
| | Pancreatitis | 4 | 2012 | 130 | 0.680 |
Why?
| | Delivery of Health Care | 1 | 2020 | 296 | 0.660 |
Why?
| | Spinal Cord | 1 | 2017 | 252 | 0.650 |
Why?
| | United States | 17 | 2021 | 6119 | 0.650 |
Why?
| | National Institutes of Health (U.S.) | 2 | 2021 | 104 | 0.630 |
Why?
| | Triage | 3 | 2020 | 97 | 0.610 |
Why?
| | Physician-Patient Relations | 1 | 2020 | 576 | 0.580 |
Why?
| | Anastomotic Leak | 2 | 2014 | 99 | 0.580 |
Why?
| | Pancreatic Pseudocyst | 1 | 2014 | 23 | 0.580 |
Why?
| | History, 20th Century | 5 | 2021 | 316 | 0.570 |
Why?
| | Pancreatic Fistula | 2 | 2011 | 14 | 0.560 |
Why?
| | Peer Review | 1 | 2013 | 19 | 0.550 |
Why?
| | Transplantation, Autologous | 12 | 2021 | 321 | 0.550 |
Why?
| | Choristoma | 1 | 2014 | 74 | 0.550 |
Why?
| | Endocytosis | 3 | 2010 | 190 | 0.540 |
Why?
| | Gastrointestinal Motility | 1 | 2013 | 31 | 0.540 |
Why?
| | Lactones | 2 | 2003 | 33 | 0.530 |
Why?
| | Capsaicin | 1 | 2012 | 47 | 0.520 |
Why?
| | TRPV Cation Channels | 1 | 2012 | 19 | 0.520 |
Why?
| | Protein Kinase C-delta | 2 | 2010 | 28 | 0.510 |
Why?
| | Potassium Channels | 3 | 2004 | 346 | 0.510 |
Why?
| | Congresses as Topic | 1 | 2013 | 118 | 0.500 |
Why?
| | Carbachol | 4 | 2005 | 39 | 0.500 |
Why?
| | Cholangitis | 1 | 2012 | 22 | 0.500 |
Why?
| | Choledocholithiasis | 1 | 2012 | 10 | 0.500 |
Why?
| | Duodenal Diseases | 1 | 2012 | 23 | 0.490 |
Why?
| | Workload | 2 | 2020 | 120 | 0.480 |
Why?
| | Specialty Boards | 1 | 2011 | 27 | 0.480 |
Why?
| | Gastrointestinal Diseases | 1 | 2013 | 147 | 0.480 |
Why?
| | Postoperative Complications | 7 | 2017 | 2242 | 0.480 |
Why?
| | Adenocarcinoma | 2 | 2013 | 1213 | 0.480 |
Why?
| | Cell Line | 12 | 2012 | 2597 | 0.480 |
Why?
| | Biomedical Research | 2 | 2021 | 345 | 0.470 |
Why?
| | Diverticulum | 1 | 2012 | 41 | 0.470 |
Why?
| | Laparoscopy | 4 | 2020 | 697 | 0.470 |
Why?
| | Periodicals as Topic | 1 | 2013 | 166 | 0.470 |
Why?
| | Clinical Competence | 3 | 2020 | 681 | 0.460 |
Why?
| | Internship and Residency | 5 | 2020 | 878 | 0.460 |
Why?
| | Colectomy | 1 | 2012 | 181 | 0.450 |
Why?
| | Cost Savings | 1 | 2010 | 62 | 0.440 |
Why?
| | Blood Glucose | 4 | 2021 | 884 | 0.430 |
Why?
| | Pancreatic Cyst | 1 | 2010 | 39 | 0.430 |
Why?
| | Bile Acids and Salts | 2 | 2011 | 46 | 0.430 |
Why?
| | Career Choice | 1 | 2011 | 132 | 0.420 |
Why?
| | Gallbladder Neoplasms | 1 | 2010 | 31 | 0.420 |
Why?
| | Clathrin | 1 | 2009 | 29 | 0.420 |
Why?
| | Health Expenditures | 1 | 2010 | 71 | 0.420 |
Why?
| | Societies, Medical | 4 | 2020 | 523 | 0.420 |
Why?
| | Cholecystectomy, Laparoscopic | 1 | 2010 | 43 | 0.410 |
Why?
| | Neoadjuvant Therapy | 3 | 2020 | 269 | 0.410 |
Why?
| | Program Development | 1 | 2010 | 136 | 0.400 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2010 | 223 | 0.400 |
Why?
| | Universities | 3 | 2019 | 132 | 0.390 |
Why?
| | Cooperative Behavior | 1 | 2010 | 169 | 0.390 |
Why?
| | Critical Care | 3 | 2020 | 351 | 0.380 |
Why?
| | Male | 32 | 2020 | 41036 | 0.360 |
Why?
| | Chicago | 4 | 2020 | 1416 | 0.360 |
Why?
| | Ultrasonography, Interventional | 2 | 2020 | 113 | 0.360 |
Why?
| | Intestinal Diseases | 2 | 2009 | 80 | 0.360 |
Why?
| | Drainage | 3 | 2015 | 170 | 0.360 |
Why?
| | Membrane Proteins | 3 | 2011 | 1187 | 0.350 |
Why?
| | Blood Proteins | 1 | 2007 | 154 | 0.350 |
Why?
| | Hospital Mortality | 1 | 2009 | 325 | 0.350 |
Why?
| | Female | 29 | 2020 | 43684 | 0.350 |
Why?
| | Muscarinic Agonists | 2 | 2005 | 23 | 0.350 |
Why?
| | Islets of Langerhans | 3 | 2021 | 537 | 0.340 |
Why?
| | Abdominal Pain | 4 | 2021 | 125 | 0.340 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2020 | 1171 | 0.330 |
Why?
| | Carcinoma | 1 | 2010 | 431 | 0.330 |
Why?
| | Membrane Transport Proteins | 2 | 2005 | 158 | 0.320 |
Why?
| | Risk Assessment | 5 | 2020 | 2239 | 0.320 |
Why?
| | History, 21st Century | 3 | 2021 | 178 | 0.310 |
Why?
| | History, 19th Century | 2 | 2021 | 58 | 0.310 |
Why?
| | Diabetes Mellitus | 1 | 2012 | 702 | 0.310 |
Why?
| | Insulin-Secreting Cells | 2 | 2021 | 394 | 0.310 |
Why?
| | Bicarbonates | 1 | 2005 | 70 | 0.310 |
Why?
| | Membrane Glycoproteins | 1 | 2007 | 428 | 0.300 |
Why?
| | Clotrimazole | 1 | 2004 | 3 | 0.300 |
Why?
| | Charybdotoxin | 1 | 2004 | 8 | 0.300 |
Why?
| | Splenic Artery | 1 | 2004 | 9 | 0.300 |
Why?
| | Dogs | 4 | 2017 | 790 | 0.290 |
Why?
| | Digestive System Abnormalities | 1 | 2004 | 12 | 0.290 |
Why?
| | Thrombin | 1 | 2004 | 59 | 0.290 |
Why?
| | Hemostatics | 1 | 2004 | 47 | 0.290 |
Why?
| | Diarrhea | 1 | 2005 | 204 | 0.280 |
Why?
| | Aneurysm, False | 1 | 2004 | 57 | 0.280 |
Why?
| | Wound Healing | 2 | 2004 | 347 | 0.280 |
Why?
| | Middle Aged | 22 | 2020 | 25178 | 0.280 |
Why?
| | Schools, Medical | 1 | 2005 | 112 | 0.280 |
Why?
| | Gastric Bypass | 1 | 2005 | 98 | 0.270 |
Why?
| | Physics | 1 | 2003 | 19 | 0.270 |
Why?
| | Transplantation | 1 | 2003 | 43 | 0.260 |
Why?
| | Necrosis | 3 | 2012 | 205 | 0.260 |
Why?
| | Ammonia | 1 | 2003 | 40 | 0.260 |
Why?
| | Stents | 3 | 2020 | 373 | 0.260 |
Why?
| | Docosahexaenoic Acids | 1 | 2003 | 33 | 0.260 |
Why?
| | Gastroenterology | 2 | 2016 | 112 | 0.260 |
Why?
| | Collagen | 1 | 2004 | 273 | 0.260 |
Why?
| | Protein Transport | 5 | 2010 | 419 | 0.250 |
Why?
| | Health Care Costs | 1 | 2005 | 219 | 0.250 |
Why?
| | Adult | 20 | 2020 | 25396 | 0.250 |
Why?
| | Treatment Outcome | 14 | 2021 | 7692 | 0.250 |
Why?
| | Embolization, Therapeutic | 1 | 2004 | 214 | 0.250 |
Why?
| | Obesity, Morbid | 1 | 2005 | 198 | 0.250 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2012 | 918 | 0.250 |
Why?
| | Tight Junctions | 1 | 2003 | 140 | 0.240 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2004 | 367 | 0.240 |
Why?
| | Ion Channels | 1 | 2004 | 257 | 0.240 |
Why?
| | Reoperation | 2 | 2017 | 619 | 0.240 |
Why?
| | Regeneration | 1 | 2003 | 152 | 0.240 |
Why?
| | History, 15th Century | 1 | 2021 | 6 | 0.240 |
Why?
| | History, 16th Century | 1 | 2021 | 9 | 0.240 |
Why?
| | Biotinylation | 2 | 2012 | 40 | 0.240 |
Why?
| | History, 17th Century | 1 | 2021 | 12 | 0.240 |
Why?
| | History, Medieval | 1 | 2021 | 12 | 0.240 |
Why?
| | Breast Neoplasms | 3 | 2020 | 2731 | 0.240 |
Why?
| | History, 18th Century | 1 | 2021 | 23 | 0.240 |
Why?
| | Isoenzymes | 1 | 2002 | 276 | 0.240 |
Why?
| | History, Ancient | 1 | 2021 | 67 | 0.240 |
Why?
| | Information Services | 1 | 2001 | 28 | 0.230 |
Why?
| | Awards and Prizes | 1 | 2021 | 32 | 0.230 |
Why?
| | Receptor, erbB-2 | 2 | 2020 | 186 | 0.230 |
Why?
| | Societies, Scientific | 1 | 2001 | 40 | 0.230 |
Why?
| | Rats, Sprague-Dawley | 4 | 2017 | 1365 | 0.230 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 3 | 2007 | 72 | 0.230 |
Why?
| | Intestines | 1 | 2004 | 423 | 0.220 |
Why?
| | Anastomosis, Roux-en-Y | 3 | 2012 | 29 | 0.220 |
Why?
| | Geriatric Assessment | 2 | 2014 | 156 | 0.220 |
Why?
| | Critical Illness | 1 | 2003 | 269 | 0.220 |
Why?
| | Immunohistochemistry | 3 | 2012 | 1806 | 0.220 |
Why?
| | Animals | 14 | 2017 | 26575 | 0.220 |
Why?
| | Risk | 2 | 2020 | 692 | 0.220 |
Why?
| | Uncertainty | 1 | 2020 | 56 | 0.220 |
Why?
| | Up-Regulation | 1 | 2003 | 705 | 0.210 |
Why?
| | Efficiency, Organizational | 1 | 2020 | 57 | 0.210 |
Why?
| | Quality of Life | 3 | 2017 | 1277 | 0.210 |
Why?
| | Antibody Formation | 1 | 2020 | 203 | 0.210 |
Why?
| | Hydrogen-Ion Concentration | 3 | 2007 | 550 | 0.210 |
Why?
| | Fatty Liver | 1 | 2021 | 122 | 0.210 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 2223 | 0.200 |
Why?
| | Students | 1 | 2020 | 124 | 0.200 |
Why?
| | Pseudomonas aeruginosa | 2 | 2011 | 203 | 0.200 |
Why?
| | Operating Rooms | 1 | 2020 | 112 | 0.200 |
Why?
| | Clinical Trials as Topic | 2 | 2020 | 1183 | 0.200 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2002 | 688 | 0.190 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2020 | 148 | 0.190 |
Why?
| | Antibodies, Viral | 1 | 2020 | 320 | 0.190 |
Why?
| | Physician's Role | 1 | 2020 | 185 | 0.190 |
Why?
| | Fasting | 1 | 2018 | 173 | 0.180 |
Why?
| | Health Status | 1 | 2020 | 350 | 0.180 |
Why?
| | Tomography, X-Ray Computed | 4 | 2014 | 2533 | 0.180 |
Why?
| | Internet | 1 | 2020 | 321 | 0.180 |
Why?
| | Blotting, Western | 2 | 2012 | 832 | 0.180 |
Why?
| | Reperfusion Injury | 2 | 2011 | 154 | 0.180 |
Why?
| | Sepsis | 2 | 2011 | 291 | 0.170 |
Why?
| | Gene Expression Regulation | 2 | 2005 | 1918 | 0.170 |
Why?
| | Patient Readmission | 2 | 2017 | 278 | 0.170 |
Why?
| | Attitude of Health Personnel | 2 | 2020 | 639 | 0.160 |
Why?
| | Abdominal Abscess | 1 | 2015 | 18 | 0.160 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2012 | 2082 | 0.160 |
Why?
| | Academic Medical Centers | 3 | 2010 | 386 | 0.150 |
Why?
| | Tissue Preservation | 1 | 2015 | 14 | 0.150 |
Why?
| | Cultural Diversity | 1 | 2016 | 56 | 0.150 |
Why?
| | Medical Staff, Hospital | 1 | 2016 | 112 | 0.150 |
Why?
| | Pain, Postoperative | 1 | 2017 | 228 | 0.150 |
Why?
| | Escherichia coli Infections | 1 | 2015 | 52 | 0.150 |
Why?
| | Sodium-Bicarbonate Symporters | 2 | 2005 | 8 | 0.150 |
Why?
| | Cells, Cultured | 4 | 2005 | 2949 | 0.150 |
Why?
| | Surgery, Computer-Assisted | 2 | 2017 | 106 | 0.140 |
Why?
| | Follow-Up Studies | 5 | 2019 | 3811 | 0.140 |
Why?
| | Pancreatic Hormones | 1 | 2014 | 13 | 0.140 |
Why?
| | Chloride Channels | 2 | 2005 | 46 | 0.140 |
Why?
| | Survival Analysis | 4 | 2014 | 1586 | 0.140 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 906 | 0.140 |
Why?
| | Endoscopy | 2 | 2017 | 299 | 0.140 |
Why?
| | Cholangitis, Sclerosing | 1 | 2013 | 43 | 0.140 |
Why?
| | Referral and Consultation | 1 | 2016 | 318 | 0.140 |
Why?
| | Bryostatins | 2 | 2003 | 15 | 0.130 |
Why?
| | Incidence | 3 | 2019 | 1587 | 0.130 |
Why?
| | Calcium | 2 | 2012 | 1216 | 0.130 |
Why?
| | Microscopy, Fluorescence | 3 | 2011 | 441 | 0.130 |
Why?
| | Hormone Replacement Therapy | 1 | 2014 | 63 | 0.130 |
Why?
| | Macrolides | 2 | 2003 | 32 | 0.130 |
Why?
| | Cell Polarity | 2 | 2005 | 120 | 0.130 |
Why?
| | California | 1 | 2013 | 134 | 0.130 |
Why?
| | Diterpenes | 1 | 2012 | 22 | 0.130 |
Why?
| | Insulin | 4 | 2014 | 1156 | 0.130 |
Why?
| | Hypersensitivity | 2 | 2007 | 135 | 0.130 |
Why?
| | Risk Factors | 4 | 2017 | 5279 | 0.130 |
Why?
| | Acrylamides | 1 | 2012 | 31 | 0.130 |
Why?
| | Databases, Factual | 3 | 2017 | 797 | 0.130 |
Why?
| | Electric Conductivity | 1 | 2012 | 153 | 0.130 |
Why?
| | Pancreatic Diseases | 1 | 2012 | 57 | 0.130 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2014 | 171 | 0.130 |
Why?
| | Antibiotic Prophylaxis | 2 | 2011 | 79 | 0.130 |
Why?
| | Abscess | 1 | 2012 | 102 | 0.130 |
Why?
| | Kidney | 3 | 2009 | 1209 | 0.120 |
Why?
| | Chronic Pain | 1 | 2013 | 95 | 0.120 |
Why?
| | Aged | 9 | 2020 | 18161 | 0.120 |
Why?
| | Time Factors | 4 | 2019 | 5437 | 0.120 |
Why?
| | Jejunum | 1 | 2012 | 105 | 0.120 |
Why?
| | Acute Disease | 1 | 2014 | 851 | 0.120 |
Why?
| | Cell Membrane | 3 | 2005 | 693 | 0.120 |
Why?
| | Duodenum | 1 | 2012 | 105 | 0.120 |
Why?
| | Child | 5 | 2021 | 6516 | 0.120 |
Why?
| | Healthcare Disparities | 1 | 2016 | 320 | 0.120 |
Why?
| | Conflict of Interest | 1 | 2011 | 61 | 0.110 |
Why?
| | Debridement | 1 | 2011 | 66 | 0.110 |
Why?
| | Pseudomonas Infections | 1 | 2011 | 96 | 0.110 |
Why?
| | Regional Health Planning | 1 | 2010 | 13 | 0.110 |
Why?
| | National Health Programs | 1 | 2010 | 19 | 0.110 |
Why?
| | Laparoscopes | 1 | 2011 | 17 | 0.110 |
Why?
| | Cost Control | 1 | 2010 | 46 | 0.110 |
Why?
| | Enzyme Inhibitors | 3 | 2004 | 671 | 0.110 |
Why?
| | Research | 2 | 2003 | 256 | 0.110 |
Why?
| | Antineoplastic Agents | 1 | 2002 | 2335 | 0.110 |
Why?
| | Dopamine | 1 | 2012 | 288 | 0.110 |
Why?
| | Cystadenoma, Mucinous | 1 | 2010 | 8 | 0.110 |
Why?
| | Rats | 4 | 2009 | 4331 | 0.110 |
Why?
| | Cystadenoma, Serous | 1 | 2010 | 16 | 0.110 |
Why?
| | Cystadenoma, Papillary | 1 | 2010 | 8 | 0.110 |
Why?
| | Ions | 1 | 2010 | 72 | 0.110 |
Why?
| | Recurrence | 1 | 2014 | 1165 | 0.110 |
Why?
| | Mice, Inbred C57BL | 3 | 2012 | 3136 | 0.110 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 2 | 2020 | 29 | 0.110 |
Why?
| | Financing, Government | 1 | 2010 | 23 | 0.110 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2010 | 43 | 0.110 |
Why?
| | Polyethylene Glycols | 2 | 2011 | 389 | 0.110 |
Why?
| | Adolescent | 8 | 2019 | 8911 | 0.110 |
Why?
| | Algorithms | 2 | 2012 | 1818 | 0.110 |
Why?
| | Liver Neoplasms | 2 | 2007 | 615 | 0.110 |
Why?
| | Neoplasm Staging | 2 | 2020 | 1900 | 0.110 |
Why?
| | Polymers | 1 | 2011 | 223 | 0.110 |
Why?
| | Radiation Injuries, Experimental | 1 | 2009 | 48 | 0.100 |
Why?
| | United States Food and Drug Administration | 1 | 2010 | 119 | 0.100 |
Why?
| | Research Support as Topic | 1 | 2010 | 79 | 0.100 |
Why?
| | Protein Isoforms | 1 | 2010 | 266 | 0.100 |
Why?
| | DNA, Complementary | 2 | 2007 | 409 | 0.100 |
Why?
| | Autoantigens | 1 | 2010 | 131 | 0.100 |
Why?
| | Membrane Microdomains | 1 | 2009 | 65 | 0.100 |
Why?
| | Intestine, Small | 1 | 2011 | 340 | 0.100 |
Why?
| | Radiation-Protective Agents | 1 | 2009 | 101 | 0.100 |
Why?
| | Adenoviridae | 1 | 2010 | 346 | 0.100 |
Why?
| | RNA Interference | 1 | 2010 | 377 | 0.100 |
Why?
| | Doxorubicin | 2 | 2020 | 293 | 0.100 |
Why?
| | Ileum | 1 | 2009 | 186 | 0.100 |
Why?
| | Signal Transduction | 4 | 2005 | 3274 | 0.100 |
Why?
| | Professional Autonomy | 2 | 2020 | 40 | 0.100 |
Why?
| | Liver | 2 | 2012 | 1216 | 0.090 |
Why?
| | Positron-Emission Tomography | 1 | 2010 | 277 | 0.090 |
Why?
| | Methylamines | 1 | 2007 | 5 | 0.090 |
Why?
| | Rubidium Radioisotopes | 1 | 2007 | 5 | 0.090 |
Why?
| | Reference Values | 2 | 2011 | 686 | 0.090 |
Why?
| | Biological Transport, Active | 1 | 2007 | 104 | 0.090 |
Why?
| | Guideline Adherence | 1 | 2010 | 220 | 0.090 |
Why?
| | Jejunostomy | 1 | 2007 | 18 | 0.090 |
Why?
| | Endoscopy, Digestive System | 1 | 2008 | 76 | 0.090 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2010 | 266 | 0.090 |
Why?
| | Retrospective Studies | 6 | 2021 | 7284 | 0.090 |
Why?
| | Severity of Illness Index | 3 | 2017 | 1738 | 0.090 |
Why?
| | Plasmids | 1 | 2007 | 293 | 0.090 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 438 | 0.090 |
Why?
| | Surgical Instruments | 2 | 2005 | 62 | 0.090 |
Why?
| | Length of Stay | 2 | 2014 | 685 | 0.090 |
Why?
| | Adenosine Triphosphatases | 1 | 2007 | 153 | 0.090 |
Why?
| | Immunization | 1 | 2007 | 160 | 0.080 |
Why?
| | Young Adult | 5 | 2019 | 5784 | 0.080 |
Why?
| | Glucose | 1 | 2009 | 611 | 0.080 |
Why?
| | Protein Kinase C-alpha | 2 | 2004 | 30 | 0.080 |
Why?
| | Carbazoles | 2 | 2004 | 52 | 0.080 |
Why?
| | Enterohepatic Circulation | 1 | 2005 | 4 | 0.080 |
Why?
| | Carbonic Anhydrase Inhibitors | 1 | 2005 | 3 | 0.080 |
Why?
| | 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid | 1 | 2005 | 19 | 0.080 |
Why?
| | Stilbenes | 1 | 2005 | 24 | 0.080 |
Why?
| | Antiporters | 1 | 2005 | 24 | 0.080 |
Why?
| | Survival Rate | 2 | 2014 | 1933 | 0.080 |
Why?
| | Autoimmunity | 2 | 2010 | 161 | 0.080 |
Why?
| | Anti-Bacterial Agents | 1 | 2011 | 776 | 0.080 |
Why?
| | Electrophysiology | 2 | 2004 | 436 | 0.080 |
Why?
| | Ohio | 1 | 2005 | 37 | 0.080 |
Why?
| | Biological Transport | 2 | 2004 | 410 | 0.080 |
Why?
| | Blotting, Northern | 1 | 2005 | 272 | 0.080 |
Why?
| | Intestinal Absorption | 1 | 2005 | 137 | 0.080 |
Why?
| | Cholinergic Agonists | 1 | 2004 | 9 | 0.070 |
Why?
| | Mesenteric Veins | 1 | 2005 | 36 | 0.070 |
Why?
| | Barium | 1 | 2004 | 35 | 0.070 |
Why?
| | Ischemic Preconditioning | 1 | 2005 | 37 | 0.070 |
Why?
| | Injections, Intralesional | 1 | 2004 | 40 | 0.070 |
Why?
| | Dissection | 1 | 2005 | 47 | 0.070 |
Why?
| | Autoimmune Diseases | 1 | 2007 | 231 | 0.070 |
Why?
| | Membrane Potentials | 2 | 2004 | 484 | 0.070 |
Why?
| | Disease-Free Survival | 2 | 2020 | 1195 | 0.070 |
Why?
| | Phosphorylation | 2 | 2004 | 1148 | 0.070 |
Why?
| | Age Factors | 1 | 2009 | 1904 | 0.070 |
Why?
| | Neutrophil Infiltration | 1 | 2004 | 25 | 0.070 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2005 | 96 | 0.070 |
Why?
| | Aged, 80 and over | 3 | 2014 | 6483 | 0.070 |
Why?
| | Myosin Light Chains | 1 | 2003 | 29 | 0.070 |
Why?
| | Salmonella typhimurium | 1 | 2004 | 35 | 0.070 |
Why?
| | Drug Combinations | 1 | 2004 | 237 | 0.070 |
Why?
| | Biliary Fistula | 1 | 2003 | 8 | 0.070 |
Why?
| | Microscopy, Electron | 1 | 2004 | 526 | 0.070 |
Why?
| | Chlorine | 1 | 2003 | 13 | 0.070 |
Why?
| | Suture Techniques | 1 | 2005 | 139 | 0.070 |
Why?
| | Indoles | 2 | 2004 | 327 | 0.070 |
Why?
| | Stimulation, Chemical | 1 | 2003 | 68 | 0.070 |
Why?
| | Radioisotopes | 1 | 2003 | 40 | 0.070 |
Why?
| | Quantum Theory | 1 | 2003 | 26 | 0.070 |
Why?
| | Mice | 3 | 2012 | 10937 | 0.070 |
Why?
| | Ultrasonics | 1 | 2003 | 34 | 0.070 |
Why?
| | Dinoprostone | 1 | 2003 | 69 | 0.070 |
Why?
| | Fatal Outcome | 1 | 2004 | 306 | 0.070 |
Why?
| | Growth Substances | 1 | 2003 | 88 | 0.070 |
Why?
| | Chimera | 1 | 2003 | 56 | 0.070 |
Why?
| | Professional Practice | 1 | 2003 | 55 | 0.070 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2003 | 79 | 0.070 |
Why?
| | Tritium | 1 | 2002 | 139 | 0.070 |
Why?
| | Electric Impedance | 1 | 2003 | 92 | 0.070 |
Why?
| | Focal Adhesions | 1 | 2003 | 69 | 0.070 |
Why?
| | Thapsigargin | 1 | 2002 | 54 | 0.070 |
Why?
| | Mannitol | 1 | 2002 | 51 | 0.060 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2002 | 46 | 0.060 |
Why?
| | Reproducibility of Results | 1 | 2010 | 2622 | 0.060 |
Why?
| | Ion Transport | 1 | 2003 | 83 | 0.060 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2002 | 84 | 0.060 |
Why?
| | Cost-Benefit Analysis | 1 | 2005 | 400 | 0.060 |
Why?
| | Cell Membrane Permeability | 1 | 2003 | 132 | 0.060 |
Why?
| | Iodine Radioisotopes | 1 | 2002 | 139 | 0.060 |
Why?
| | Epithelium | 1 | 2003 | 315 | 0.060 |
Why?
| | Health Care Surveys | 2 | 2016 | 303 | 0.060 |
Why?
| | Carcinogens | 1 | 2002 | 106 | 0.060 |
Why?
| | Tumor Cells, Cultured | 1 | 2004 | 1080 | 0.060 |
Why?
| | Microfilament Proteins | 1 | 2004 | 198 | 0.060 |
Why?
| | Radiography | 1 | 2004 | 864 | 0.060 |
Why?
| | Education, Medical | 1 | 2005 | 204 | 0.060 |
Why?
| | Liver Diseases | 1 | 2004 | 214 | 0.060 |
Why?
| | Drug Interactions | 1 | 2002 | 270 | 0.060 |
Why?
| | Potassium | 1 | 2003 | 303 | 0.060 |
Why?
| | Practice Guidelines as Topic | 1 | 2010 | 1064 | 0.060 |
Why?
| | Cystic Fibrosis | 1 | 2003 | 127 | 0.060 |
Why?
| | Ultrasonography | 1 | 2004 | 676 | 0.060 |
Why?
| | Receptors, Cell Surface | 1 | 2003 | 293 | 0.060 |
Why?
| | Cell Division | 1 | 2003 | 749 | 0.060 |
Why?
| | Cytoskeleton | 1 | 2002 | 185 | 0.060 |
Why?
| | Reconstructive Surgical Procedures | 1 | 2005 | 273 | 0.060 |
Why?
| | Body Mass Index | 1 | 2005 | 757 | 0.060 |
Why?
| | Immunization, Passive | 1 | 2020 | 78 | 0.060 |
Why?
| | Social Problems | 1 | 2020 | 10 | 0.060 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2003 | 388 | 0.060 |
Why?
| | Antigens, CD | 1 | 2002 | 483 | 0.050 |
Why?
| | Organizational Innovation | 1 | 2020 | 35 | 0.050 |
Why?
| | Bacterial Adhesion | 2 | 2011 | 92 | 0.050 |
Why?
| | Cell Movement | 1 | 2004 | 736 | 0.050 |
Why?
| | Epidemics | 1 | 2020 | 31 | 0.050 |
Why?
| | Education, Distance | 1 | 2020 | 22 | 0.050 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2003 | 307 | 0.050 |
Why?
| | Computer-Assisted Instruction | 1 | 2020 | 48 | 0.050 |
Why?
| | Taxoids | 1 | 2020 | 131 | 0.050 |
Why?
| | Colonic Neoplasms | 1 | 2004 | 547 | 0.050 |
Why?
| | Antibodies, Neutralizing | 1 | 2020 | 125 | 0.050 |
Why?
| | Cyclophosphamide | 1 | 2020 | 286 | 0.050 |
Why?
| | Virulence | 2 | 2011 | 272 | 0.050 |
Why?
| | Colorectal Neoplasms | 1 | 2007 | 828 | 0.050 |
Why?
| | Actins | 1 | 2002 | 427 | 0.050 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2020 | 79 | 0.050 |
Why?
| | Cytokines | 1 | 2003 | 742 | 0.050 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2019 | 24 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2004 | 2069 | 0.050 |
Why?
| | Receptors, Steroid | 1 | 2019 | 44 | 0.050 |
Why?
| | Violence | 1 | 2020 | 109 | 0.050 |
Why?
| | C-Peptide | 1 | 2018 | 171 | 0.050 |
Why?
| | Immunoglobulin G | 1 | 2020 | 469 | 0.050 |
Why?
| | Health Personnel | 1 | 2020 | 170 | 0.050 |
Why?
| | Prospective Studies | 2 | 2018 | 3903 | 0.050 |
Why?
| | Cross Infection | 1 | 2020 | 192 | 0.050 |
Why?
| | Proportional Hazards Models | 1 | 2020 | 868 | 0.050 |
Why?
| | Organ Transplantation | 1 | 2001 | 268 | 0.040 |
Why?
| | Risk Adjustment | 1 | 2017 | 29 | 0.040 |
Why?
| | Hypoglycemic Agents | 2 | 2014 | 365 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2019 | 320 | 0.040 |
Why?
| | Learning | 1 | 2020 | 259 | 0.040 |
Why?
| | Propensity Score | 1 | 2017 | 135 | 0.040 |
Why?
| | Bacterial Proteins | 1 | 2004 | 893 | 0.040 |
Why?
| | Stress, Psychological | 1 | 2020 | 305 | 0.040 |
Why?
| | Paclitaxel | 1 | 2019 | 449 | 0.040 |
Why?
| | Pain Management | 1 | 2017 | 122 | 0.040 |
Why?
| | Cultural Competency | 1 | 2016 | 26 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2020 | 1367 | 0.040 |
Why?
| | Palliative Care | 1 | 2017 | 250 | 0.040 |
Why?
| | Models, Biological | 1 | 2003 | 1787 | 0.040 |
Why?
| | Program Evaluation | 1 | 2016 | 303 | 0.040 |
Why?
| | Interviews as Topic | 1 | 2016 | 328 | 0.040 |
Why?
| | Anastomosis, Surgical | 1 | 2016 | 298 | 0.040 |
Why?
| | Educational Measurement | 1 | 2016 | 201 | 0.040 |
Why?
| | Narcotics | 1 | 2014 | 68 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 561 | 0.030 |
Why?
| | Frail Elderly | 1 | 2014 | 62 | 0.030 |
Why?
| | Asthma | 1 | 2001 | 831 | 0.030 |
Why?
| | Quality Improvement | 1 | 2017 | 350 | 0.030 |
Why?
| | Apoptosis | 2 | 2011 | 1763 | 0.030 |
Why?
| | C-Reactive Protein | 1 | 2013 | 184 | 0.030 |
Why?
| | Illinois | 1 | 2014 | 449 | 0.030 |
Why?
| | Hepatectomy | 2 | 2004 | 155 | 0.030 |
Why?
| | Deoxycholic Acid | 1 | 2011 | 10 | 0.030 |
Why?
| | Bacterial Translocation | 1 | 2011 | 45 | 0.030 |
Why?
| | Financial Support | 1 | 2011 | 7 | 0.030 |
Why?
| | Phenols | 1 | 2011 | 39 | 0.030 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2011 | 29 | 0.030 |
Why?
| | Benzhydryl Compounds | 1 | 2011 | 42 | 0.030 |
Why?
| | Caco-2 Cells | 1 | 2011 | 144 | 0.030 |
Why?
| | Caspase 3 | 1 | 2011 | 175 | 0.030 |
Why?
| | Organizational Policy | 1 | 2011 | 53 | 0.030 |
Why?
| | Random Allocation | 1 | 2011 | 371 | 0.030 |
Why?
| | Transplantation, Homologous | 1 | 2013 | 1016 | 0.030 |
Why?
| | Chronic Disease | 2 | 2005 | 952 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 382 | 0.030 |
Why?
| | Leadership | 1 | 2011 | 113 | 0.030 |
Why?
| | Phosphoproteins | 1 | 2011 | 266 | 0.030 |
Why?
| | Clone Cells | 1 | 2010 | 300 | 0.030 |
Why?
| | Interpersonal Relations | 1 | 2011 | 174 | 0.030 |
Why?
| | Molecular Weight | 1 | 2009 | 369 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2011 | 903 | 0.020 |
Why?
| | Vaccination | 1 | 2010 | 195 | 0.020 |
Why?
| | Ethics, Medical | 1 | 2011 | 310 | 0.020 |
Why?
| | Administration, Oral | 1 | 2009 | 709 | 0.020 |
Why?
| | Cholesterol | 1 | 2009 | 432 | 0.020 |
Why?
| | Colitis, Ulcerative | 1 | 2013 | 646 | 0.020 |
Why?
| | Intraoperative Period | 1 | 2007 | 101 | 0.020 |
Why?
| | Prognosis | 1 | 2014 | 3619 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2010 | 844 | 0.020 |
Why?
| | Acidosis, Renal Tubular | 1 | 2005 | 11 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2010 | 1857 | 0.020 |
Why?
| | Mesenteric Artery, Superior | 1 | 2005 | 22 | 0.020 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2005 | 77 | 0.020 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2010 | 529 | 0.020 |
Why?
| | RNA, Complementary | 1 | 2004 | 9 | 0.020 |
Why?
| | Xenopus laevis | 1 | 2005 | 141 | 0.020 |
Why?
| | Kidney Tubules, Proximal | 1 | 2005 | 67 | 0.020 |
Why?
| | Phenylalanine | 1 | 2004 | 41 | 0.020 |
Why?
| | Immunotherapy | 1 | 2010 | 535 | 0.020 |
Why?
| | Amino Acid Motifs | 1 | 2004 | 118 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2011 | 2248 | 0.020 |
Why?
| | Xenopus | 1 | 2004 | 130 | 0.020 |
Why?
| | Membranes | 1 | 2004 | 39 | 0.020 |
Why?
| | Subcellular Fractions | 1 | 2004 | 100 | 0.020 |
Why?
| | Cytoplasm | 1 | 2005 | 284 | 0.020 |
Why?
| | Oocytes | 1 | 2005 | 228 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2004 | 282 | 0.020 |
Why?
| | Stress Fibers | 1 | 2003 | 24 | 0.020 |
Why?
| | Ligation | 1 | 2003 | 57 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2010 | 1596 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2004 | 300 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2008 | 1584 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2005 | 736 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2004 | 297 | 0.020 |
Why?
| | Mutation, Missense | 1 | 2005 | 274 | 0.020 |
Why?
| | Gene Deletion | 1 | 2004 | 343 | 0.020 |
Why?
| | Adenosine Triphosphate | 1 | 2003 | 306 | 0.020 |
Why?
| | Genetic Vectors | 1 | 2004 | 448 | 0.020 |
Why?
| | Pain Measurement | 1 | 2003 | 297 | 0.020 |
Why?
| | Transfection | 1 | 2004 | 942 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2004 | 766 | 0.020 |
Why?
| | Intraoperative Complications | 1 | 2003 | 187 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2004 | 1055 | 0.010 |
Why?
| | Analgesics, Opioid | 1 | 2005 | 354 | 0.010 |
Why?
| | Pain | 1 | 2003 | 350 | 0.010 |
Why?
| | Peptides | 1 | 2003 | 632 | 0.010 |
Why?
| | Biopsy | 1 | 2004 | 1165 | 0.010 |
Why?
| | Cohort Studies | 1 | 2005 | 2626 | 0.010 |
Why?
| | DNA | 1 | 2004 | 1291 | 0.010 |
Why?
| | Mutation | 1 | 2004 | 3779 | 0.010 |
Why?
|
|
Matthews's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|